The efficacy of activated protein C for the treatment of sepsis: Incorporating observational evidence with a Bayesian approach

BMJ Open

Volumn 5, Issue 1, 2015, Pages

  Zhang, Zhongheng ^a  

^a ZHEJIANG NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; FIBRINOLYTIC AGENT; PROTEIN C;

ARTICLE; BAYES THEOREM; DATA BASE; DRUG EFFICACY; HUMAN; METHODOLOGY; MORTALITY; OBSERVATIONAL METHOD; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SEPSIS; SEQUENTIAL ANALYSIS; STATISTICAL SIGNIFICANCE; FEMALE; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY;

BAYES THEOREM; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; OBSERVATIONAL STUDIES AS TOPIC; PROTEIN C; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SEPSIS;

EID: 84921884971     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-006524     Document Type: Article

References (38)

1. Schorr CA, Zanotti S, Dellinger RP. Severe sepsis and septic shock: management and performance improvement. Virulence 2014;5:190-9.
2. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580-637.
3. MacIntyre N. Ventilatory management of ALI/ARDS. Semin Respir Crit Care Med 2006;27:396-403.
4. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.
5. Pro CI, Yealy DM, Kellum JA, et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med 2014;370:1683-93.
6. Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000;356:26-30.
7. Zhang Z, Xu X, Zhu H. Intensive- vs less-intensive-dose continuous renal replacement therapy for the intensive care unit-related acute kidney injury: a meta-analysis and systematic review. J Crit Care 2010;25:595-600.
8. Christiaans SC, Wagener BM, Esmon CT, et al. Protein C and acute inflammation: a clinical and biological perspective. Am J Physiol Lung Cell Mol Physiol 2013;305:L455-66.
9. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
10. Dhainaut JF, Payet S, Vallet B, et al. Cost-effectiveness of activated protein C in real-life clinical practice. Crit Care 2007;11:R99.
11. Kubler A, Mayzner-Zawadzka E, Durek G, et al. Results of severe sepsis treatment program using recombinant human activated protein C in Poland. Med Sci Monit 2006;12:CR107-12.
12. Annane D, Timsit JF, Megarbane B, et al. Recombinant human activated protein C for adults with septic shock: a randomized controlled trial. Am J Respir Crit Care Med 2013;187:1091-7.
13. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012;366:2055-64.
14. Lai PS, Matteau A, Iddriss A, et al. An updated meta-analysis to understand the variable efficacy of drotrecogin alfa (activated) in severe sepsis and septic shock. Minerva Anestesiol 2013;79:33-43.
15. Marti-Carvajal AJ, Sola I, Gluud C, et al. Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients. Cochrane Database Syst Rev 2012;12:CD004388.
16. Zhang Z, Ni H, Xu X. Do the observational studies using propensity score analysis agree with randomized controlled trials in the area of sepsis? J Crit Care 2014;29:886.e9-15.
17. Zhang Z. Recombinant human activated protein C for the treatment of severe sepsis and septic shock: a study protocol for incorporating observational evidence using a Bayesian approach. BMJ Open 2014;4:e005622.
18. Chen MH, Ibrahim JG. Power prior distributions for regression models. Stat Sci 2000;15:46-60.
19. Wetterslev J, Thorlund K, Brok J, et al. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 2008;61:64-75.
20. Bernard GR, Ely EW, Wright TJ, et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001;29:2051-9.
21. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005;353:1332-41.
22. Nadel S, Goldstein B, Williams MD, et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007;369:836-43.
23. Dhainaut JF, Antonelli M, Wright P, et al. Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock. Intensive Care Med 2009;35:1187-95.
24. de Pont AC, Bakhtiari K, Hutten BA, et al. Recombinant human activated protein C resets thrombin generation in patients with severe sepsis - a case control study. Crit Care 2005;9:R490-7.
25. Bertolini G, Rossi C, Anghileri A, et al. Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. Intensive Care Med 2007;33:426-34.
26. Rowan KM, Welch CA, North E, et al. Drotrecogin alfa (activated): real-life use and outcomes for the UK. Crit Care 2008;12:R58.
27. Vincent JL, Laterre PF, Decruyenaere J, et al. A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units - an observational study. Acta Clin Belg 2008;63:25-30.
28. Martin G, Brunkhorst FM, Janes JM, et al. The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes. Crit Care 2009;13:R103.
29. Lindenauer PK, Rothberg MB, Nathanson BH, et al. Activated protein C and hospital mortality in septic shock: a propensity-matched analysis. Crit Care Med 2010;38:1101-7.
30. Sadaka F, O'Brien J, Migneron M, et al. Activated protein C in septic shock: a propensity-matched analysis. Crit Care 2011;15:R89.
31. Casserly B, Gerlach H, Phillips GS, et al. Evaluating the use of recombinant human activated protein C in adult severe sepsis: results of the Surviving Sepsis Campaign. Crit Care Med 2012;40:1417-26.
32. Rimmer E, Kumar A, Doucette S, et al. Activated protein C and septic shock: a propensity-matched cohort study∗. Crit Care Med 2012;40:2974-81.
33. Onukwugha E. Improving confidence in observational studies: should statistical analysis plans be made publicly available? Pharmaco Econ 2013;31:177-9.
34. Anand V, Scales DC, Parshuram CS, et al. Registration and design alterations of clinical trials in critical care: a cross-sectional observational study. Intensive Care Med 2014;40:700-22.
35. Kalil AC, Florescu DF. Severe sepsis: are PROWESS and PROWESS-SHOCK trials comparable? A clinical and statistical heterogeneity analysis. Crit Care 2013;17:167.
36. Albert RK. " Lies, damned lies..." and observational studies in comparative effectiveness research. Am J Respir Crit Care Med 2013;187:1173-7.
37. Nallamothu BK, Hayward RA, Bates ER. Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation 2008;118:1294-303.
38. Zhang Z. Big data and clinical research: focusing on the area of critical care medicine in mainland China. Quant Imaging Med Surg 2014;4:426-9.